Showing 1751-1760 of 2050 results for "".
- Oertli’s CataRhex 3 Device Now Equipped With Speep Pump Innovationhttps://modernod.com/news/oertlis-catarhex-3-device-now-equipped-with-speep-pump-innovation/2479420/Oertli Instrumente has expanded the CataRhex 3 to include the pump innovation, “SPEEP,” which is designed to provide more efficiency and precision in cataract surgery due to precise control of flow and vacuum. The CataRhex 3 is Oertli’s compact and portable surgical platf
- CDC Calls for Masks in Schools, Hard-Hit Areas, Even if Vaccinatedhttps://modernod.com/news/cdc-calls-for-masks-in-schools-hard-hit-areas-even-if-vaccinated/2479417/The Centers for Disease Control and Prevention (CDC) once again is recommending that some Americans wear masks indoors. The agency called today for masks in K-12 school settings and in areas of the United States experiencing high or substantial SARS-CoV-2 transmission, even for the fully vaccinat
- Monty Montoya Appointed CEO of TherOptixhttps://modernod.com/news/monty-montoya-appointed-ceo-of-theroptix/2479395/Monty Montoya has been named chief executive officer of TherOptix, a preclinical biopharma company focused on delivering clinically impactful therapeutics via a drug-eluting contact lens platform. TherOptix has received orphan drug designation on its lead candidate (001) for prevention of prolife
- FDA, CDC Say No Need for COVID-19 Booster Vaccines in US At This Timehttps://modernod.com/news/fda-cdc-say-no-need-for-covid-19-booster-vaccines-in-us-at-this-time/2479358/The FDA and the US Centers for Disease Control and Prevention (CDC) said that people who have been fully immunized against COVID-19 do not require a booster vaccine at this time, according to a FirstWord report. The jo
- Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officerhttps://modernod.com/news/outlook-therapeutics-appoints-c-russell-trenary-iii-as-president-and-chief-executive-officer/2479350/Outlook Therapeutics announced the appointment of C. Russell Trenary III as President, Chief Executive Officer and a member of the Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics’ President, CEO and CFO since June 2018, will continue serving as CFO and as a member o
- Oasis TEARS PF PLUS Preservative-Free Lubricant Eye Drops Now Delivered in a Bottlehttps://modernod.com/news/oasis-tears-pf-plus-preservative-free-lubricant-eye-drops-now-delivered-in-a-bottle/2479338/Oasis Medical is launching Oasis TEARS PF PLUS preservative-free lubricant eye drops delivered in a 10mL bottle for multiuse. Lubricant eye drops, which are packaged in traditional multi-use bottles, contain preservatives to prevent microbial growth. Preservative-free lubricant eye drops a
- Johnson & Johnson Vision Announces Launch of Tecnis Synergy and Tecnis Synergy Toric II PC-IOLs in US and Canadahttps://modernod.com/news/johnson-johnson-vision-announces-launch-of-tecnis-synergy-and-tecnis-synergy-toric-ii-pc-iols-in-us-and-canada/2479320/Johnson & Johnson Vision announced the availability of Tecnis Synergy and Tecnis Synergy Toric II IOLs in the United States and Canada. These next-generation PC-IOLs combine the best of extended depth of focus and multifocal technologies to deliver the widest range of continuous vision and th
- Belkin Laser Appoints Andrew Webb as Chief Commercial Officerhttps://modernod.com/news/belkin-laser-appoints-andrew-webb-as-chief-commercial-officer/2479316/Israel-based medical device company Belkin Laser has announced the appointment of Andrew Webb as Chief Commercial Officer. Under Mr. Webb’s guidance, the company’s commercial and go-to-market strategy will be rolled out in anticipation of a controlled launch in
- Oyster Point Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial for Patients with Neurotrophic Keratopathyhttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-the-olympia-phase-2-clinical-trial-for-patients-with-neurotrophic-keratopathy/2479308/Oyster Point Pharma announced enrollment of the first subject in the OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy (NK). “This is an exciting milestone as we continue to develop this potentially new tr
- Even Inactive Thyroid Eye Disease Adversely Impacts Patientshttps://modernod.com/news/even-inactive-thyroid-eye-disease-adversely-impacts-patients/2479264/Ocular signs and symptoms of thyroid eye disease (TED) often persist beyond the active phase of the condition, with many patients continuing to experience mental health issues and diminished quality of life, new research suggests, as reported<